The short version of RP-HPLC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-30 and is reviewed periodically as new material appears.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Gly-His-Lys | Three amino acids, histidine in the middle |
| Complex formula | C14H22CuN6O4 | One copper(II) ion per peptide |
| Molar mass (complex) | approx. 402.9 g/mol | Depends on counterion and hydration state |
| Appearance | Blue to blue-violet solid | Colour arises from copper coordination |
| Common synonyms | Copper tripeptide-1, GHK-Cu | Naming varies between disciplines |
Aqueous GHK-Cu solutions are less stable than the dry powder. Light, dissolved oxygen and elevated temperature all accelerate loss of the intact complex, and the main observable changes are fading of the blue colour and the appearance of peptide fragments. Acidic conditions protonate the histidine imidazole and weaken copper binding, while strongly alkaline conditions promote hydrolysis of the peptide backbone. Because several degradation routes operate at once, a single shelf-life figure does not describe all storage conditions.
Solid material is typically kept as a lyophilised powder in a sealed, light-protected container at minus 20 degrees Celsius, with desiccant where humidity is high. Working solutions are often prepared fresh, aliquoted and frozen to avoid repeated freeze-thaw cycles. Glassware and buffers are checked for trace metal contamination, since other transition metals can displace copper. Records of lot number, reconstitution date and storage temperature help trace unexpected colour changes. Blue colour itself is not a reliable purity test, because partly degraded solutions can remain visibly coloured.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
CD49b receptor is located on Natural killer cells, Natural killer T cells, and certain types of activated T cell. It mediates migration and cell-to-cell interactions within tissue microenvironments. As for the use of the receptor in immunology, the co-expression of the CD49b receptor with the lymphocyte activation gene 3 receptor (LAG-3) is widely used in studies as a phenotypic marker of Tr1 regulatory T cell, which is a particular type of regulatory T cell responsible for maintaining immune tolerance. Not only in physiological conditions, but also in the case of pathologies, the integrin α2β1 participates in tissue remodeling and turnover of extracellular matrix. The pathway of collagen signal transduction through the integrin α2β1 controls collagen production and other aspects of matrix organization. The pathology in case of disorders of this process may be observed in fibrosis, whereas dysregulation of α2β1 integrin expression is linked to metastasis and tumor invasion. It may be concluded that integrin α2β1 is a functional molecule, and not only a molecular structure for adhesion.
Another synonymous mutation (c.3156C>T) was proposed to introduce a cryptic donor site, resulting in aberrant splicing, a theory which subsequently was confirmed in several families with ERED from different countries.
In normal bone, fractures occur when there is significant force applied or repetitive trauma over a long time. Fractures can also occur when a bone is weakened, such as with osteoporosis, or when there is a structural problem, such as when the bone remodels excessively (such as Paget's disease) or is the site of the growth of cancer. Common fractures include wrist fractures and hip fractures, associated with osteoporosis, vertebral fractures associated with high-energy trauma and cancer, and fractures of long-bones. Not all fractures are painful. When serious, depending on the fractures type and location, complications may include flail chest, compartment syndromes or fat embolism. Compound fractures involve the bone's penetration through the skin. Some complex fractures can be treated by the use of bone grafting procedures that replace missing bone portions. Fractures and their underlying causes can be investigated by X-rays, CT scans and MRIs. Fractures are described by their location and shape, and several classification systems exist, depending on the location of the fracture. A common long bone fracture in children is a Salter–Harris fracture. When fractures are managed, pain relief is often given, and the fractured area is often immobilised. This is to promote bone healing. In addition, surgical measures such as internal fixation may be used. Because of the immobilisation, people with fractures are often advised to undergo rehabilitation.
Sources: en.wikipedia.org
=== Disadvantages === The used fuel is difficult and dangerous to reprocess because many of the daughters of 232Th and 233U are strong gamma emitters. All 233U production methods result in impurities of 232U, either from parasitic knock-out (n,2n) reactions on 232Th, 233Pa, or 233U that result in the loss of a neutron, or from double neutron capture of 230Th, an impurity in natural 232Th:
With the expiration of many patents for blockbuster biologics between 2012 and 2019, the interest in biosimilar production, i.e., follow-on biologics, has increased. Compared to small molecules that consist of chemically identical active ingredients, biologics are vastly more complex and consist of a multitude of subspecies. Due to their heterogeneity and the high process sensitivity, originators and follow-on biosimilars will exhibit variability in specific variants over time. The safety and clinical performance of both originator and biosimilar biopharmaceuticals must remain equivalent throughout their lifecycle. Process variations are monitored by modern analytical tools (e.g., liquid chromatography, immunoassays, mass spectrometry, etc.) and describe a unique design space for each biologic. Biosimilars require a different regulatory framework compared to small-molecule generics. Legislation in the 21st century has addressed this by recognizing an intermediate ground of testing for biosimilars. The filing pathway requires more testing than for small-molecule generics, but less testing than for registering completely new therapeutics. In 2003, the European Medicines Agency introduced an adapted pathway for biosimilars, termed similar biological medicinal products. This pathway is based on a thorough demonstration of comparability of the product to an existing approved product.
As the Pizarro approached the Canary Islands, it passed Lanzarote on 16 June 1799, where Humboldt and Bonpland observed volcanic landscapes, including the Timanfaya volcano, which had last erupted in the 1730s. Navigation among the islands was challenging due to fog and unpredictable winds. The crew mistook a rock formation on Graciosa for a coastal castle, and the ship narrowly avoided being driven onto rocks by strong currents during the night. On 19 June 1799, the Pizarro arrived near Grand Canary. Dense fog delayed progress, but as it cleared, the ship’s company saw Pico del Teide, the volcanic peak of Tenerife, which Humboldt and Bonpland intended to ascend. British warships were observed nearby, but the Pizarro was protected by the guns of a Spanish fort and continued safely.
Sources: en.wikipedia.org
Carlos Outeiral, CASP14: what Google DeepMind's AlphaFold 2 really achieved, and what it means for protein folding, biology and bioinformatics, Oxford Protein Informatics Group. (3 December) Mohammed AlQuraishi, AlphaFold2 @ CASP14: "It feels like one's child has left home." (blog), 8 December 2020 Mohammed AlQuraishi, The AlphaFold2 Method Paper: A Fount of Good Ideas (blog), 25 July 2021 AlphaFold-3 web server AlphaFold v2.1 code and links to model on GitHub Open access to protein structure predictions for the human proteome and 20 other key organisms at European Bioinformatics Institute (AlphaFold Protein Structure Database) CASP 14 website AlphaFold: The making of a scientific breakthrough, DeepMind, via YouTube. ColabFold, version for homooligomeric prediction and complexes
11-Aminoundecanoic acid is an organic compound with the formula H2N(CH2)10CO2H. This compound is classified as an amine and a fatty acid. 11-Aminoundecanoic acid is a precursor to Nylon-11. 11-Aminoundecanoic acid is a white crystalline and odorless solid with low solubility in water. As practiced by Arkema, 11-aminoundecanoic acid is prepared industrially from undecylenic acid, which is derived from castor oil. The synthesis proceeds in four separate reactions: Crude castor oil consists of about 80% triglycerides, from the ricinoleic acid, itself representing about 90% of the oil. It is quantitatively transesterified with methanol to methyl ricinoleate (the methyl ester of ricinoleic acid) in the presence of the basic sodium methoxide at 80 °C within 1 h reaction time in a stirred reactor.
226Ra occurs in the decay chain of uranium-238 (238U), which is the most common naturally occurring isotope of uranium. It undergoes alpha decay to radon-222, which is also radioactive; the decay chain ultimately terminates at lead-206. Because of its occurrence in the 238U decay chain, 226Ra exists naturally at low concentrations not only in uranium-containing minerals, but universally diffused in the environment (as also is uranium), as in soil and groundwater.
Sources: en.wikipedia.org
The peptide is glycyl-L-histidyl-L-lysine, a three-amino-acid sequence commonly abbreviated GHK. It binds a single copper(II) ion under typical laboratory conditions. The free peptide and the copper complex are separate chemical species with different properties.
The sequence was identified in human plasma in 1973. Early work examined its presence in blood and its proposed role in tissue repair. The copper-binding property was characterized afterward and became the focus of much later research.
The tripeptide has been measured in human plasma and other biological fluids. Whether it circulates mainly as the copper complex or as the free peptide remains an open question. Natural concentrations are low and difficult to measure reliably.
Dry powder is best kept cold, dark and sealed, typically at -20 °C for long-term storage or 2 to 8 °C for material in regular use. Vials should be warmed to room temperature before opening to prevent moisture condensing on the contents. Aqueous stock solutions degrade faster and are usually prepared fresh.